Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib versus placebo in adults with chronic inducible urticaria inadequately controlled by H1 antihistamines
MOH_2024-01-10_013011Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic inducible urticaria (CIndU) comparing Remibrutinib with Placebo (2 arms). Started Jan 2024; status: active, not recruiting.
02
Drugs
remibrutinib
03
Conditions
chronic inducible urticaria (CIndU)
Beyond the preview
Go deeper on MOH_2024-01-10_013011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-10_013011.